The Wisconsin Registry for Alzheimer's Prevention: A review of findings and current directions

نویسندگان

  • Sterling C. Johnson
  • Rebecca L. Koscik
  • Erin M. Jonaitis
  • Lindsay R. Clark
  • Kimberly D. Mueller
  • Sara E. Berman
  • Barbara B. Bendlin
  • Corinne D. Engelman
  • Ozioma C. Okonkwo
  • Kirk J. Hogan
  • Sanjay Asthana
  • Cynthia M. Carlsson
  • Bruce P. Hermann
  • Mark A. Sager
چکیده

The Wisconsin Registry for Alzheimer's Prevention is a longitudinal observational cohort study enriched with persons with a parental history (PH) of probable Alzheimer's disease (AD) dementia. Since late 2001, Wisconsin Registry for Alzheimer's Prevention has enrolled 1561 people at a mean baseline age of 54 years. Participants return for a second visit 4 years after baseline, and subsequent visits occur every 2 years. Eighty-one percent (1270) of participants remain active in the study at a current mean age of 64 and 9 years of follow-up. Serially assessed cognition, self-reported medical and lifestyle histories (e.g., diet, physical and cognitive activity, sleep, and mood), laboratory tests, genetics, and linked studies comprising molecular imaging, structural imaging, and cerebrospinal fluid data have yielded many important findings. In this cohort, PH of probable AD is associated with 46% apolipoprotein E (APOE) ε4 positivity, more than twice the rate of 22% among persons without PH. Subclinical or worse cognitive decline relative to internal normative data has been observed in 17.6% of the cohort. Twenty-eight percent exhibit amyloid and/or tau positivity. Biomarker elevations, but not APOE or PH status, are associated with cognitive decline. Salutary health and lifestyle factors are associated with better cognition and brain structure and lower AD pathophysiologic burden. Of paramount importance is establishing the amyloid and tau AD endophenotypes to which cognitive outcomes can be linked. Such data will provide new knowledge on the early temporal course of AD pathophysiology and inform the design of secondary prevention clinical trials.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Patient Engagement and its Evaluation Tools – Current Challenges and Future Directions; Comment on “Metrics and Evaluation Tools for Patient Engagement in Healthcare Organization- and System-Level Decision-Making: A Systematic Review”

Considering the growing recognition of the importance of patient engagement in healthcare decisions, research and delivery systems, it is important to ensure high quality and efficient patient engagement evaluation tools. In this commentary, we will first highlight the definition and importance of patient engagement. Then we discuss the psychometric properties of the patient engagement evaluati...

متن کامل

Verbal Fluency and Early Memory Decline: Results from the Wisconsin Registry for Alzheimer's Prevention.

This study examined the relationship between phonemic and semantic (category) verbal fluency and cognitive status in the Wisconsin Registry for Alzheimer's Prevention (WRAP), a longitudinal cohort enriched for family history of Alzheimer's disease. Participants were 283 WRAP subjects (age 53.1[6.5] years at baseline); who had completed three waves of assessment, over ∼6 years and met psychometr...

متن کامل

Amyloid burden, cortical thickness, and cognitive function in the Wisconsin Registry for Alzheimer's Prevention

There is a growing interest in understanding how amyloid-β (Aβ) accumulation in preclinical Alzheimer's disease relates to brain morphometric measures and cognition. Existing investigations in this area have been primarily conducted in older cognitively-normal (CN) individuals. Therefore, not much is known about the associations between Aβ burden, cortical thickness, and cognition in midlife. W...

متن کامل

Aging, Practice Effects, and Genetic Risk in the Wisconsin Registry for Alzheimer's Prevention.

BACKGROUND In the last five years, a consensus has developed that Alzheimer's disease (AD) may begin years before overt cognitive impairment. Accordingly, the focus has shifted to identifying preclinical disease in order to match treatments to those most likely to benefit. Subtle cognitive changes, including reduced benefit from practice, may be one such preclinical sign. In this study, we expl...

متن کامل

P 59: Non-Steroidal Anti-Inflammatory Drugs as a Prevention of Alzheimer Disease: Risks and Benefits

Alzheimer's disease (AD) is a chronic neurodegenerative disease that accounts for 60 to 80 percent of all dementia cases. The exact cause of Alzheimer`s disease is still unknown, but recent studies suggest neuro-inflammation as an important part of the pathogenesis of the disease. This brings in mind using non-steroidal anti-inflammatory drugs (NSAID) as treatment or prevention of the disease. ...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:

دوره 10  شماره 

صفحات  -

تاریخ انتشار 2018